Cash Flow Statement (Annual)

AEL / American Equity Investment Life Holding Co. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities Continuing Operations
  Net Income Loss 68,530 42,933 86,248 57,798 253,283 126,023 219,830 83,243 174,645
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Interest Sensitive And Index Product Benefits 347,883 733,218 775,757 808,479 1,272,867 1,473,700 968,053 725,472 2,023,668
    Deferred Sales Inducements Amortization Expense 39,999 59,873 71,781 87,157 253,113 131,419 209,390 251,166 176,612
    Insurance Commissions And Fees - - 76,189 89,006 103,591 118,990 136,168 173,579 200,494
    Embedded Derivative Gain Loss On Embedded Derivative Net -529,508 -130,950 105,194 -286,899 -133,968 -32,321 464,698 -543,465 -919,735
    Increase Decrease In Insurance Liabilities 9,960 43,921 76,220 35,758 14,997 2,385 5,097 12,724 -33
    Increase Decrease In Deferred Policy Acquisition Costs - - - - - 426,882 657,639 543,325 406,641
    Deferred Policy Acquisition Cost Amortization Expense 88,009 136,388 143,478 164,919 365,468 163,578 286,114 374,012 255,964
    Other Depreciation And Amortization - - - - 18,375 9,490 4,610 3,879 3,948
    Accretion Amortization Of Discounts And Premiums Investments 212,498 240,532 154,483 69,828 -6,861 14,960 8,464 -1,070 -15,431
    Gain Loss On Investments -35,492 -141 -52,617 -21,386 34,327 -6,630 -9,325 -11,155 5,879
    Equity Method Investment Dividends Or Distributions - - - - - - - - -
    Gain Loss On Derivative Instruments Net Pretax 219,154 141,719 -112,608 221,138 1,076,015 506,328 -334,300 165,727 1,678,956
    Deferred Income Tax Expense Benefit -56,150 -118,048 -80,869 -52,336 3,013 -46,504 41,916 -10,408 -46,730
    Gains Losses On Extinguishment Of Debt -675 -292 0 0 -32,515 -12,502 0 0 -18,817
    Share Based Compensation 4,630 11,993 9,339 6,552 10,476 3,544 7,373 6,692 6,464
    Increase Decrease In Accrued Investment Income Receivable 21,902 53,987 61,292 32,896 39,808 24,918 35,545 35,669 31,235
    Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable 117,817 -97,550 2,307 13,197 5,397 -19,405 -20,027 18,125 45,759
    Increase Decrease In Other Operating Assets 10,877 26,516 -5,005 7,090 -1,113 2,771 -71 -1,812 -448
    Increase Decrease In Other Policyholder Funds 8,198 103,457 177,734 55,158 -47,445 -60,931 -49,092 -34,411 -23,101
    Increase Decrease Cash Collateral From Counterparties - - - - - - -269,474 414,655 772,181
    Increase Decrease In Other Operating Liabilities 40,637 64,776 -77,082 5,927 -11,435 -51,008 75,794 -55,940 -84,416
    Increase Decrease In Other Operating Capital Net 1,759 -812 -59 857 7,059 8,948 15,962 14,089 13,794
  Net Cash Provided By Used In Operating Activities 516,551 420,475 277,791 784,314 862,668 707,786 504,804 1,414,322 1,922,393
Net Cash Provided By Used In Investing Activities
  Proceeds From Sale Maturity And Collections Of Investments
    Proceeds From Sale And Maturity Of Available For Sale Securities - - - - - - - - -
    Proceeds From Sale And Collection Of Mortgage Notes Receivable 109,969 145,754 206,741 543,211 539,240 453,937 468,102 383,763 351,255
    Proceeds From Derivative Instrument Investing Activities 79,341 492,058 506,057 483,362 971,432 1,169,874 640,467 284,470 1,697,948
    Proceeds From Sale And Maturity Of Other Investments - 0 2,274 33,601 24,050 23,165 16,792 14,045 10,571
  Payments To Acquire Investments
    Payments To Acquire Available For Sale Securities Debt 6,742,292 8,544,788 5,347,839 8,266,692 7,962,150 5,191,781 7,256,137 6,883,895 5,026,640
    Payments To Acquire Mortgage Notes Receivable 249,162 317,250 481,680 386,507 505,953 327,654 455,286 428,833 535,249
    Payments For Derivative Instrument Investing Activities 257,435 331,263 395,938 379,592 419,345 492,296 588,859 602,349 691,428
    Payments To Acquire Other Investments 46 456 77,955 86,569 29,015 72,548 13,092 11,559 305,575
  Payments To Acquire Property Plant And Equipment 2,971 5,318 5,265 738 948 1,352 1,313 1,197 4,809
  Net Cash Provided By Used In Investing Activities -2,013,730 -3,116,388 -3,605,833 -2,129,490 -3,879,296 -2,947,749 -5,577,205 -4,499,045 -2,591,936
Net Cash Provided By Used In Financing Activities
  Proceeds From Annuities And Investment Certificates 3,677,558 4,497,091 4,784,511 3,782,275 4,160,346 4,160,005 7,051,227 7,092,348 4,152,264
  Increase Decrease In Reinsurance Recoverable - - - - - - 80,777 1,317,555 6,597
  Repayments Of Annuities And Investment Certificates 1,418,797 1,465,434 1,494,554 1,575,340 1,763,913 2,025,203 2,271,950 2,535,669 2,809,486
  Payments Of Financing Costs 2,751 6,800 1,566 0 11,942 100 0 1,456 5,817
  Proceeds From Issuance Of Unsecured Debt - - - - - 0 0 0 499,650
  Repayments Of Other Long Term Debt - - - - - - 0 0 100,000
  Proceeds From Payments For In Securities Sold Under Agreements To Repurchase - - - - - - - - -
  Proceeds From Issuance Of Common Stock 1,061 6,124 4,686 5,741 31,764 13,681 112,481 139,654 14,028
  Increase Decrease In Outstanding Checks Financing Activities -8,605 -13,238 17,156 1,071 9,212 -1,252 -5,727 21,501 4,680
  Net Cash Provided By Used In Financing Activities 1,810,319 2,765,677 3,135,228 2,208,769 2,645,612 2,043,948 4,768,636 3,478,240 1,312,322
Cash And Cash Equivalents Period Increase Decrease 313,140 69,764 -192,814 863,593 -371,016 -196,015 -303,765 393,517 642,779
Cash And Cash Equivalents At Carrying Value - - - - - 701,514 397,749 791,266 1,434,045
Supplemental Cash Flow Information
  Interest Paid
    Interest Paid 19,669 25,802 30,650 27,666 25,608 42,989 39,118 39,647 55,445
  Income Taxes Paid Net
    Income Taxes Paid 191,878 143,748 129,250 67,450 128,225 132,754 91,887 39,066 142,627
  Non Cash Operating Activity
    Deferred Sales Inducements Additions 292,791 370,714 385,123 306,659 337,787 330,079 486,924 353,966 216,172

Peers - Life Insurance (6311)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 025676206